Speaker Profile

M.D., Ph.D., Founder and Chairman, Parthen Inc.

Dr. Leyland-Jones’ principal academic contributions have been in the fields of anticancer therapy development, the pharmacodynamics, pharmacokinetics, and pharmacogenetics of oncological clinical trials, the translation of preclinical models into the clinic, biomarker endpoints in Phase I/II clinical trials, and screening and mechanistic studies of novel targeted and chemotherapeutic anticancer agents. He has authored and co-authored more than 210 peer-reviewed articles and book contributions, 25 books and book chapters, 425 abstracts and 35 patents.

Clinical Dx Showcase:
Parthen Inc.

Parthen has a singular mission – to expand precision medicine to all people regardless of background, income or geographic location. This will be accomplished through a novel, virtual collaboration with front line physicians in communities around the world.

Precision Medicine for All
The time has come to move precision medicine away from current expensive and exclusive practices and into the community setting. Parthen is developing a new approach to lower costs, increase availability and provide a concierge experience to all people.

 Session Abstract – PMWC 2022 Silicon Valley

Track 6, June 28-30

The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative